News Releases

Date Title
12/05/17
Summary ToggleSunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017 -Company announces vecabrutinib as generic name for SNS-062- -Event on December 9 in Atlanta, GA with Slide Webcast- SOUTH SAN FRANCISCO, Calif. , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced it will provide a program update for SNS-062, generic name
12/04/17
Summary ToggleSunesis Pharmaceuticals Announces Change in Leadership - Daniel Swisher Resigns as CEO Effective End of 2017; t o Remain with Sunesis as a Strategic Advisor - - Board Member Dayton Misfeldt Appointed Interim CEO Effective January 2018 ; Board Starting Retained Search for Permanent Replacement - SOUTH SAN FRANCISCO, Calif. , Dec.
11/30/17
Summary ToggleSunesis Pharmaceuticals Appoints William Quinn as Chief Financial Officer and Senior Vice President, Finance and Corporate Development SOUTH SAN FRANCISCO, Calif. , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the appointment of William Quinn as Chief Financial Officer and Senior Vice President, Finance and Corporate Development. Willie brings deep and relevant healthcare industry
11/02/17
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 2:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the third quarter ended September 30, 2017 .
10/27/17
Summary ToggleSunesis to Host Conference Call on November 2nd to Discuss Third Quarter 2017 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, November 2, 2017 at 2:00 p.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended
10/25/17
Summary ToggleSunesis Announces Pricing of $20 Million Offering of Securities SOUTH SAN FRANCISCO, Calif. , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the pricing of underwritten public offerings of (i) 7,500,000 shares of its common stock and accompanying warrants to purchase 3,750,000 shares of its common stock and (ii)
10/24/17
Summary ToggleSunesis Announces Proposed Public Offering of Common Stock, Preferred Stock and Warrants SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series D Convertible Preferred Stock, each in combination with
08/31/17
Summary ToggleSunesis to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the company will present at two upcoming investor conferences. Daniel Swisher , Chief Executive Officer of Sunesis, will present at the Wells Fargo Securities 2017
07/27/17
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 2:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , July 27, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the second quarter ended June 30, 2017 . Loss from operations for the three months ended
07/24/17
Summary ToggleSunesis to Host Conference Call on July 27th to Discuss Second Quarter 2017 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , July 24, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, July 27, 2017 at 2:00 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June
07/18/17
Summary ToggleSunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies SOUTH SAN FRANCISCO, Calif. , July 18, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the first patient has been dosed at the Dana-Farber Institute in the Phase 1b/2 dose-escalation and cohort-expansion study of its reversible, non-covalent Bruton’s
06/26/17
Summary ToggleSunesis Pharmaceuticals Added to Russell Microcap® Index SOUTH SAN FRANCISCO, Calif. , June 26, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it was added to the Russell Microcap® Index when the Russell Investment Group reconstituted its family of U.S. indexes effective today, June 26, 2017 .
06/23/17
Summary ToggleSunesis Pharmaceuticals Announces Presentation of Updated Results from Washington University-Sponsored Phase 1/Cohort Expansion Trial of Vosaroxin Plus Azacitidine in Patients with MDS at the EHA Annual Meeting Vosaroxin Combination Demonstrates Encouraging Response Rates SOUTH SAN FRANCISCO, Calif. , June 23, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of updated results from a Washington University -sponsored Phase 1/Cohort Expansion trial of
05/08/17
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 2:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 08, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the first quarter ended March 31, 2017 . Loss from operations for the three months ended
05/01/17
Summary ToggleSunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML Company’s Primary Development Focus is Non-Covalent Reversible BTK-Inhibitor SNS-062 Sunesis to Host Conference Call and Webcast in Conjunction with First Quarter 2017 Financial Results on Monday, May 8 th at 11:00 AM ET SOUTH SAN FRANCISCO, Calif. , May 01, 2017 (GLOBE NEWSWIRE) -- Sunesis
04/03/17
Summary ToggleSunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting SOUTH SAN FRANCISCO, Calif. , April 03, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced results from an Ohio State University -sponsored preclinical study evaluating the efficacy of non-covalent BTK inhibitor SNS-062 in chronic lymphocytic leukemia (CLL)
03/28/17
Summary ToggleSunesis Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference SOUTH SAN FRANCISCO, Calif. , March 28, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Executive Vice President Corporate Development and Finance and Chief Financial Officer of Sunesis, will present at the 16 th Annual Needham Healthcare
03/22/17
Summary ToggleSunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin SOUTH SAN FRANCISCO, Calif. , March 22, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has submitted its responses to the European Medicine Agency (EMA) Day 180 List of Outstanding Issues issued by the Committee for Medicinal Products for Human Use
03/09/17
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 11:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , March 09, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2016 .
03/02/17
Summary ToggleSunesis to Host Conference Call on March 9th to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , March 02, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 9, 2017 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year
03/01/17
Summary ToggleSunesis Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif. , March 01, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will present at the Cowen and Company 37 th Annual Health Care Conference on Wednesday, March 8 th at 10:40 AM
02/06/17
Summary ToggleSunesis Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference SOUTH SAN FRANCISCO, Calif. , Feb. 06, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will present at the 19 th Annual BIO CEO & Investor Conference on Monday, February 13 th at 5:30 PM Eastern Time at
01/23/17
Summary ToggleSunesis Pharmaceuticals Announces Clinical and Regulatory Updates to SNS-062 and Vosaroxin Programs FDA Review of Investigational New Drug Application for SNS-062 Complete; Phase 1B/2 Study in Patients with Advanced B-Cell Malignancies to Begin Dosing in the First Half of 2017 Vosaroxin Day 180 List of Outstanding Issues Received; Company to go Before Scientific Advisory Group in April Prior to